首页|免疫检查点抑制剂相关性肝毒性研究进展

免疫检查点抑制剂相关性肝毒性研究进展

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)作为肿瘤治疗领域近年来取得的重大进展之一,通过阻断免疫抑制进而重新激活T细胞,恢复其对肿瘤细胞的杀伤发挥抗肿瘤作用,极从而大程度地改善肿瘤患者的生存获益.但ICIs在发挥作用的同时也会非特异性激活免疫系统,导致免疫耐受失衡,损伤正常器官组织,这类不良事件即为免疫相关不良反应(immune-related adverse events,irAEs).随着ICIs的广泛应用,其引发的irAEs的数量及类型不断增多已成为不容忽视的临床问题.其中,免疫检查点抑制剂相关性肝毒性(ICI-induced immune mediated hepatitis,IMH)作为一种潜在的致命性不良反应,对于其时间及结果尚无透彻的研究.
Immune checkpoint inhibitor-induced immune-mediated hepatitis:Review and outlook
As one of the major advances in tumor therapy in recent years,immune checkpoint inhibitors(ICIs)can greatly improve the survival of tumor patients by blocking immunosuppression and reactivating T cells to resume their anti-tumor effects on tumor cells.In addition to the protective role,ICIs can also activate the immune system non-specifically,leading to an imbalance of immune tolerance and damages to normal organs and tissues,which are known as immune-related adverse events(irAEs).With the wide application of ICIs,the increasing number and types of ICI-induced irAEs have become a clinical problem that cannot be ignored.Among them,ICI-induced immune-mediated hepatitis(IMH)is a potentially fatal adverse event that has not been thoroughly studied for its timing and outcome.

immune-mediated hepatitisimmunotherapyimmune-related adverse eventsimmune checkpoint inhibitorsprogrammed cell death protein-1(PD-1)/programmed death-ligand-1(PD-L1)cytotoxic T lymphocyte antigen 4(CTLA-4)

李瑜文、张俊萍

展开 >

030032 太原市,山西医科大学第三医院山西白求恩医院

免疫相关性肝毒性 免疫治疗 免疫不良反应 免疫检查抑制剂 PD-1/PD-L1,细胞毒性T淋巴细胞抗原4

山西省自然科学基金

201901D111421

2024

10.3969/j.issn.1002-7386.2024.16.029

河北医药
河北省医学情报研究所

河北医药

CSTPCD
影响因子：1.075
ISSN：1002-7386
年,卷(期)：2024.46(16)